Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.

Target Disease

R&D focused on Neurological & Autoimmune Incurable Disease

  • 01 ALS: Amyotrophic Lateral Sclerosis

    Marketed (KR)

    Progressive neurodegenerative disease leads to muscle atrophy due to death of motor nerve cells

  • 02 MSA: Multiple System Atrophy

    Phase I (KR)

    Neurological degenerative disease similar symptoms with Parkinsonism, but non-response of Dopamine medicine

  • 03 Anoxic Brain Injury

    Death of nerve cells because of oxygen deficit in brain

  • 04 Refractory Epilepsy

    Incurable disease of inoperable and non-responseof anti-seizure drug

  • 05 SLE: Systemic Lupus Erythematosus

    Phase I (KR)

    Recrudescent auto-immune disease causes systemic inflammatory response syndrome

Research Area
Neurological Diseases

Medical conditions in which motor control, perception, sensation, and the autonomic nervous system functions abnormally due to the death or loss of nerve cells.

  • Amyotrophic Lateral Sclerosis
  • Stroke
  • Alzheimer’s Disease
  • Multiple Sclerosis
  • Parkinson Disease
  • Spinal Cord Injury
Autoimmune Diseases

A pathological state in which the body’s immune system attacks healthy cells or tissues. Symptoms and types of autoimmune disease very depending on which parts of the body are attacked or destroyed by immune cells.

  • Systemic Lupus Erythematosus
  • Atopic Dermatitis
  • Rheumatoid Arthritis
  • Optic Neuritis
  • Graft Versus Host Disease
  • Diabetes Mellitus
  • Crohn’s Disease
Rare disease

At first we are offering stem cell treatment for a disease area that’s no cure and patients suffering from incurable and rare disease. We developed the world’s first stem cell therapeutic product for ALS (Amyotrophic Lateral Sclerosis) name of NEURONATA-R, is an autologous bone marrow mesenchymal stem cell (autologous BM-MSC) therapy.

Corestem is dedicated the development of a treatment for rare disease area such as ALS and Lupus where has higher market potential, faster growth rate, less competitor, and expertise track of orphan drug. As the characteristic advantage of rare disease, our strategy focuses on niche markets; high-value drugs for rare diseases of low prevalence, but for which a high return on investment could be reaped